Related and Nonrelated Parties [Axis]
Related Party [Member]
Nonrelated Party [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Treasury Stock, Common [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Investment, Name [Axis]
Octomera LLC [Member]
ORGS [Member]
Long-Lived Tangible Asset [Axis]
Production Facility [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Equipment [Member]
Office Equipment [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Know How [Member]
Technology [Member]
Metalmark [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Unit Purchase Agreement [Member]
Debt Instrument [Axis]
10 Secured Promissory Notes [Member]
Business Combination [Axis]
Octomera [Member]
Know How Technology [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 3 [Member]
Measurement Input Type [Axis]
Measurement Input, Discount Rate [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Long-Term Revenue Growth Rate [Member]
Measurement Input Standard Deviation [Member]
Measurement Input Trigger Event [Member]
Measurement Input Trigger Events [Member]
Measurement Input, Revenue Multiple [Member]
Butterfly Biosciences Sarl [Member]
Revacel Srl [Member]
Legal Entity [Axis]
Revatis [Member]
Equity Method Investment, Nonconsolidated Investee [Axis]
Segments [Axis]
Therapies [Member]
Eliminations [Member]
Securities Purchase Agreement [Member]
Sale of Stock [Axis]
Private Placement [Member]
Title and Position [Axis]
Investor [Member]
Warrant [Member]
Class of Warrant or Right [Axis]
Warrant One [Member]
Office Furniture and Computers [Member]
Lab Equipment [Member]
Advance Payment [Member]
Geographical [Axis]
BELGIUM
GREECE
NETHERLANDS
ISRAEL
UNITED STATES
Long-Term Debt [Member]
Short-Term Debt [Member]
Short Term Debt One [Member]
Short Term Debt Two [Member]
Short Term Debt Three [Member]
Debt Exchange Agreements [Member]
April 07, 2024 [Member]
April 05 2024 [Member]
August 21 2024 [Member]
August 21 2024 One [Member]
September 06 2024 [Member]
September 10 2024 [Member]
September 09 2024 [Member]
September 17 2024 [Member]
September 30 2024 [Member]
October 03 2024 [Member]
October 22 2024 [Member]
October 30 2024 [Member]
November 04 2024 [Member]
November 14 2024 [Member]
November 15 2024 [Member]
November 29 2024 [Member]
December 13 2024 [Member]
December 19 2024 [Member]
November 30 2024 [Member]
December 31 2024 [Member]
December 31 2024 One [Member]
December 31 2024 Two [Member]
December 31 2024 Three [Member]
December 31 2024 Four [Member]
December 31 2024 Five [Member]
December 31 2024 Six [Member]
December 31 2024 Seven [Member]
December 31 2024 Eight [Member]
Loan Agreement [Member]
Long-Term Debt, Type [Axis]
Convertible Loans One [Member]
Convertible Loans Two [Member]
Convertible Loans Three [Member]
Convertible Loans Four [Member]
Convertible Loans [Member]
Convertible Loans Five [Member]
Convertible Loans Six [Member]
Convertible Loans Seven [Member]
Convertible Loans Eight [Member]
Convertible Loans Nine [Member]
Convertible Loans Repaid One [Member]
Counterparty Name [Axis]
Three Convertible Debt Holders [Member]
Related Party Transaction [Axis]
Koligo Therapeutics Inc [Member]
Lender [Member]
Borrower [Member]
Convertible Loan Agreements [Member]
Offshore Investor [Member]
Manufacturing Facility [Member]
Offices [Member]
Collaboration And License Agreements Axis
TelHashomer Medical Research Infrastructure and Services Ltd Thm [Member]
Scenario [Axis]
PhaseI Clinical Trials [Member]
PhaseII Clinical Trials [Member]
Phase III Clinical Trials [Member]
First Product By The FDA [Member]
Worldwide Net Sales Of Products [Member]
Sales Milestone [Member]
Israelus Binational Industrial Research And Development Foundation [Member]
Columbia License Agreement [Member]
California University Joint Research Agreement [Member]
Ownership [Axis]
Caerus Therapeutics Inc [Member]
Tissue Genesis, LLC [Member]
Savicell Agreement [Member]
Stromatis Agreement [Member]
HMGU [Member]
European Innovation Council And SMEs Executive Agency [Member]
Grant Funding Agreement [Member]
Product and Service [Axis]
Grants From Other [Member]
Consolidated Entities [Axis]
Subsidiaries [Member]
Grant [Member]
Mircod LLC [Member]
SubLicense Agreements [Member]
Deep Med IO Ltd [Member]
Joint Venture Agreement [Member]
Asset Purchase Agreement [Member]
Antidilutive Securities [Axis]
Options, RSUs and Warrants [Member]
Shares upon Conversion of Convertible Loans [Member]
Plan Name [Axis]
2017 Equity Incentive Plan [Member]
Global Share Incentive Plan 2012 [Member]
Employee Stock Ownership Plan (ESOP) Name [Axis]
Options Granted to Employees and Directors [Member]
Masthercell Global [Member]
Options Granted To Non Employees [Member]
Options Granted To Employees [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Employees [Member]
Director [Member]
Exercise Price Range [Axis]
Exercise Price One [Member]
Exercise Price Two [Member]
Exercise Price Three [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
Exercise Price Six [Member]
Exercise Price Seven [Member]
Exercise Price Eight [Member]
Exercise Price Nine [Member]
Exercise Price Ten [Member]
Exercise Price Eleven [Member]
Exercise Price Twelve [Member]
Exercise Price Thirteen [Member]
Exercise Price Fourteen [Member]
Exercise Price Fifteen [Member]
Exercise Price Sixteen [Member]
Exercise Price Seventeen [Member]
Exercise Price Eighteen [Member]
Exercise Price Nineteen [Member]
Exercise Price Twenty [Member]
Exercise Price Twenty One [Member]
Exercise Price Twenty Two [Member]
Exercise Price Twenty Three [Member]
Exercise Price Twenty Four [Member]
Exercise Price Twenty Five [Member]
Exercise Price Twenty Six [Member]
Exercise Price Twenty Seven [Member]
Exercise Price Twenty Eight [Member]
Cell Process Development Services And Hospital Services [Member]
License Fees [Member]
Customer [Axis]
Customer A [Member]
Customer B [Member]
Customer C [Member]
Customer D [Member]
Statement Of Income Location Balance [Axis]
Research And Development Expenses [Member]
Broaden [Member]
Theracell [Member]
Orgenesis Biotech Israel Limited [Member]
Orgenesis Korea [Member]
Orgenesis Belgium SRL And Orgenesis SRL [Member]
Orgenesis Belgium SRL [Member]
Orgenesis Services SRL [Member]
Operating Activities [Axis]
Continuing Operations [Member]
Executive Officer [Member]
Board Members [Member]
Nonexecutive Directors [Member]
Southern Israel Bridging Fund Two LP [Member]
Mr Amir Hasidim [Member]
Unsecured Convertible Note Agreements [Member]
Consultation Agreement [Member]
Unsecured Convertible Note Two Agreements [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Equity Purchase Agreement [Member]
Registration Rights Agreement [Member]
Williamsburg Venture Holdings LLC [Member]
Convertible Loan Agreement [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated By Reference
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Auditor Firm ID
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Assets
CURRENT ASSETS:
Cash and cash equivalents
Restricted cash
Accounts receivable, net of credit losses of December 31, 2024 $14,281 ($0 as of December 31, 2023)
Prepaid expenses and other receivables
Receivables from related parties
Inventory
Total current assets
NON CURRENT ASSETS:
Deposits
Equity investees
Property, plants and equipment, net
Intangible assets, net
Operating lease right-of-use assets
Goodwill
Other assets
Total non-current assets
TOTAL ASSETS
Liabilities and equity
CURRENT LIABILITIES:
Short-term bank credit
Accounts payable
Accrued expenses and other payables
Income tax payable
Employees and related payables
Other payable related parties
Advance payments on account of grant
Short-term loans
Current maturities of finance leases
Current maturities of operating leases
Short-term and current maturities of convertible loans
TOTAL CURRENT LIABILITIES
LONG-TERM LIABILITIES:
Non-current operating leases
Loans payable
Convertible loans
Finance leases
Contingent consideration (see note 4)
Other long-term liabilities
TOTAL LONG-TERM LIABILITIES
TOTAL LIABILITIES
EQUITY (CAPITAL DEFICIENCY):
Common stock of $0.0001 par value Authorized at December 31, 2024 and December 31, 2023: 14,583,333 shares; Issued at December 31, 2024 and December 31, 2023: 5,199,963 and 3,216,363 shares, respectively; Outstanding at December 31, 2024 and December 31, 2023: 5,171,306 and 3,187,706 shares, respectively.
Additional paid-in capital
Accumulated other comprehensive income
Treasury stock 286,567 shares as of December 31, 2024 and December 31, 2023
Accumulated deficit
Equity attributable to Orgenesis Inc.
Non-controlling interests
TOTAL EQUITY (CAPITAL DEFICIENCY)
TOTAL LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY (CAPITAL DEFICIENCY)
Statement of Financial Position [Abstract]
Net of credit losses
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Revenues
Cost of revenues
Gross loss
Cost of development services and research and development expenses
Amortization of intangible assets
Change in Contingent consideration
Selling, general and administrative expenses included credit losses of $2,724 for the year ended December 31, 2024 and ($24,367 for the year ended December 31, 2023)
Share in net loss of associated companies
Impairment of investment
Impairment of long-lived assets
Operating loss
Loss (profit) from deconsolidation of OBI, Korea, Belgium, Services and Octomera (see note 3 and note 20)
Other income, net
Loss from extinguishment in connection with loans
Credit loss on convertible loan receivable
Financial expenses, net
Inducement expense on conversion of convertible loans
Loss before income taxes
Tax expense
Net loss
Net (loss) income attributable to non-controlling interests
Net loss attributable to Orgenesis Inc.
Loss per share:
Basic
Diluted
Weighted average number of shares used in computation of Basic and Diluted loss per share:
Basic
Diluted
Comprehensive loss:
Other Comprehensive loss – Translation adjustment
Release of translation adjustment due to deconsolidation of Orgenesis Korea and the Belgian Subsidiary in 2024 (Octomera in 2023)
Comprehensive loss
Comprehensive (loss) income attributed to non-controlling interests
Comprehensive loss attributed to Orgenesis Inc.
Credit losses expenses
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Stock-based compensation to employees and directors
RSUs vested
RSUs vested, shares
Exercise of options
Exercise of options, shares
Issuance of shares to service providers
Issuance of shares to service providers, shares
Exchange of convertible loans for equity
Exchange of convertible loans for equity, shares
Issuance of warrants with respect to convertible loans
Extinguishment in connection with convertible loan restructuring
Issuance of shares and warrants net of issuance costs
Issuance of shares and warrants net of issuance costs, shares
NCI arising from Octomera reconsolidation
Transaction with NCI (see note 3)
Issuance of Shares due to exercise of warrants
Issuance of Shares due to exercise of warrants, shares
Comprehensive income (loss) for the period
Stock-based compensation to service providers
Deconsolidation of Octomera
Adjustment to redemption value of redeemable non-controlling interest
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Convertible loans induced conversion expenses
Capital gain, net
Loss (gain) from deconsolidation of OBI, Korea and Belgium subsidiaries in 2024 (Octomera in 2023)
Share in loss of associated companies, net
Depreciation and amortization expenses
Credit loss net related to OBI, Korea and Belgium subsidiaries
Impairment of investment (see note 2)
Impairment expenses (see note 2)
Effect of exchange differences on inter-company balances
Net changes in operating leases
Interest expense accrued on loans and convertible loans
Loss from extinguishment in connection with convertible loan restructuring
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses, other accounts receivable
Inventory
Other assets
Related parties, net
Accounts payable
Accrued expenses and other payable
Employee and related payables
Deferred taxes, net
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in loan to associate entities
Purchase of property, plants and equipment
Investment in associated company
Cash acquired from acquisition of Octomera (see note 3)
Impact to cash resulting from deconsolidation of OBI, Korea and Belgium subsidiaries (see note 20)
Impact to cash resulting from deconsolidation
Investment in long-term deposits
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs)
Proceeds from issuance of convertible loans
Proceeds from transaction with redeemable non-controlling interest that do not result in a loss of control
Repayment of convertible loans and convertible bonds
Repayment of short and long-term debt
Proceeds from issuance of loans payable
Grant received in respect of third party
Receipt from Germfree (see note 13f)
Net cash provided by financing activities
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES
Right-of-use assets obtained in exchange for new finance lease liabilities
Right-of-use assets obtained in exchange for new operation lease liabilities
Increase (decrease) in accounts payable related to purchase of property, plant and equipment
Extinguishment in connection with convertible loan restructuring
CASH PAID DURING THE YEAR FOR:
Interest
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
No Insider Trading Flag
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS
SIGNIFICANT ACCOUNTING POLICIES
Reconsolidation Of Octomera Llc
RECONSOLIDATION OF OCTOMERA LLC
Equity Method Investments and Joint Ventures [Abstract]
EQUITY INVESTMENTS AND LOANS TO ASSOCIATES
Segment Reporting [Abstract]
SEGMENT INFORMATION
Equity [Abstract]
EQUITY
Property, Plant and Equipment [Abstract]
PROPERTY, PLANTS AND EQUIPMENT
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL
Loans
LOANS
Debt Disclosure [Abstract]
CONVERTIBLE LOANS
Leases
LEASES
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND LICENSE AGREEMENTS
COLLABORATIONS
Earnings Per Share [Abstract]
LOSS PER SHARE
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION
Income Tax Disclosure [Abstract]
TAXES
Revenue from Contract with Customer [Abstract]
REVENUES
Research and Development [Abstract]
COST OF DEVELOPMENT SERVICES AND RESEARCH AND DEVELOPMENT EXPENSES
Banking and Thrift Disclosure [Text Block]
FINANCIAL EXPENSES, NET
Deconsolidation Of Subsidiaries
DECONSOLIDATION OF SUBSIDIARIES
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS
LEGAL PROCEEDINGS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Use of Estimates in the Preparation of Financial Statements
Business Combination
Cash Equivalents
Cost of development services and research and development expenses
Principles of Consolidation
Non-Marketable Equity Investments
Fair value measurement
Functional Currency
Inventory
Property, Plants and Equipment
Intangible assets
Goodwill
Impairment of Long-lived Assets
Income Taxes
Stock-based Compensation
Loss per Share of Common Stock
Concentration of Credit Risk
Treasury shares
Other Comprehensive Loss
Revenue from Contracts with Customers
Leases
Segment reporting
Recently issued accounting pronouncements, not yet adopted
SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT
SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE
SCHEDULE OF PURCHASE PRICE TO THE FAIR VALUES OF THE ASSETS ACQUIRED AND LIABILITIES ASSUMED
SCHEDULE OF KEY INPUTS FOR THE FAIR VALUES VALUATION
SCHEDULE OF KEY INPUTS
SUMMARY OF RESULTS OF OPERATIONS
SCHEDULE OF CHANGES IN INVESTMENTS AND LOAN
SCHEDULE OF SEGMENT REPORTING
SCHEDULE OF WARRANTS ACTIVITY
SCHEDULE OF COMPONENTS OF PROPERTY, PLANT AND EQUIPMENT
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL AXIS
SCHEDULE OF GOODWILL
SCHEDULE OF OTHER INTANGIBLE ASSETS
SCHEDULE OF LONG TERM LOANS
SCHEDULE OF SHORT TERM LOANS
SCHEDULE OF WARRANTS GRANTED
SCHEDULE OF LONG TERM CONVERTIBLE NOTES
SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES
SCHEDULE OF LEASE COSTS
SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION
SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES
SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION
SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE
Employee Stock Ownership Plan (ESOP) [Table]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES
SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS
SCHEDULE OF STOCK OPTIONS ACTIVITY
SCHEDULE OF STOCK OPTIONS EXERCISABLE
SCHEDULE OF STOCK OPTIONS GRANTED TO EMPLOYEES
SCHEDULE OF STOCK OPTIONS ACTIVITY GRANTED TO EMPLOYEES
SCHEDULE OF SHARES AND WARRANTS GRANTS TO ADVISORS
SCHEDULE OF WARRANTS GRANTS ASSUMPTIONS
SCHEDULE OF DEFERRED TAX ASSETS
SCHEDULE OF VALUATION ALLOWANCE ACTIVITY
SCHEDULE OF DISAGGREGATION OF REVENUE
SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER
SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES
SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES
SCHEDULE OF FINANCIAL EXPENSES
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES
SCHEDULE OF RELATED PARTY TRANSACTIONS
SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS
AccountingPoliciesTable [Table]
Equity method investment, ownership percentage
Reverse stock split
Commons stock, par value
Accumulated deficit
Net cash used in operating activities
Impairment of goodwill
Property, plant and equipment
Intangible assets
Impairment of intangible assets
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Weighted average useful life
Intangible Asset, Finite-Lived [Table]
Finite-Lived Intangible Assets [Line Items]
Intangible assets and useful lives (Years)
Impairment charges of other investment
Likelihood settlement
Lease classification description
Total Contingent consideration to MM for royalty and milestone payments
Total assets acquired:
Cash and cash equivalents
Property, plants and equipment, net
Other Assets
Total assets
Total liabilities assumed:
Total current liabilities
Total long-term liabilities
Total liabilities
Know how Technology
Total Net Assets
Fair-Value of Non-controlling interests
Total liability to MM
Measurement input
Business Combination [Table]
Business Combination [Line Items]
Measurement input
Possible trigger event examination
Schedule Of Key Inputs For Fair Values Valuation Details
Shares issued
Royalty percentage to be received
Milestone payments
Milestone sales percentage
Original principal amount
Recognition of intangible asset
Liability to MM
Intangible assets useful life
Transaction cost
Revenue
Net loss
Fair value of derivative asset
Revaluation expense
Equity Method Investment [Table]
Schedule of Equity Method Investments [Line Items]
Total revenue
Gross loss
Opening balance
Investments during the period
Repayment of loan
Share in net loss of associated companies
Exchange rate differences
Total
Equity method investments
Ownership percentage
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Cost of revenues
Gross profit (loss)
Cost of development services and research and development expenses
Operating expenses
Impairment of investment
Share in net income of associated companies
Profit from deconsolidation
Other income, net
Depreciation and amortization
Loss from extinguishment in connection with convertible loan
Credit loss on convertible loan receivable
Financial Expenses, net
Finance fees related to convertible loans to equity
Income (loss) before income taxes
Number of reportable segment
Number of warrants - warrants outstanding at the beginning of the period
Weighted average exercise price - warrants outstanding at the beginning of the period
Number of warrants - issued
Weighted average exercise price - issued
Number of warrants - exercised
Weighted average exercise price - exercised
Number of warrants - expired
Weighted average exercise price - expired
Number of warrants - warrants outstanding at the end of the period
Weighted average exercise price - warrants outstanding at the end of the period
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Common stock shares issued and sell
Purchase of warrants
Exercise price of warrants
Warrant exercisable description
Warrant alternated cashless exercise description
Proceeds from private placemenrt
Stock issued during period, shares, new issues
Shares issued, price per share
Gross proceeds from offering
Offering shares
Warrant term
Transaction fees
Sale of stock, price per share
Gross proceeds from offering
Subtotal
Less – accumulated depreciation
Total
PropertyPlantAndEquipmentTable [Table]
Depreciation
Goodwill, beginning balance
Goodwill deconsolidation
Translation differences
Impairment of Goodwill
Goodwill, ending balance
Subtotal
Less - Accumulated amortization
Net carrying amount of other intangible assets
Impairment of Goodwill
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Principal amount
Interest rate
Year of maturity
Long term debt
Short term debt
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, maturity date
Number of securities called by warrants or rights
Conversion price
Date of issuance
Number of warrants
Exercise price
Expiration date
Loss on extinguishment of debt
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Line Items]
Principal Amount at Issuance
Issuance Year
Interest Rate
Current Maturity (Year)
Exercise price
Repaid, principal amount
Maturity period
Outstanding principal and accrued interest
Number of shares issued
Common stock issued
Conversion rate
Outstanding principal
Debt conversion expense
Debt instrument maturity date
Debt instrument conversion
Convertible subordinated debt
Proceeds from issuance of warrants
Share price
Schedule Of Lease-related Assets And Liabilities
Property, plants and equipment, gross
Accumulated depreciation
Property and equipment, net
Current maturities of long-term finance leases
Long-term finance leases
Weighted Average Remaining Lease Term, Operating leases
Weighted Average Remaining Lease Term, Finance leases
Weighted Average Discount Rate, Operating leases
Weighted Average Discount Rate, Finance leases
Schedule Of Lease Costs
Operating lease cost:
Amortization of leased assets
Interest on lease liabilities
Total finance lease cost
Cash paid for amounts included in the measurement of leases liabilities: Operating leases
Cash paid for amounts included in the measurement of leases liabilities: Finance leases
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Operating Leases, 2024
Finance Lease, 2024
Operating Leases, 2025
Finance Lease, 2025
Operating Leases, 2026
Finance Lease, 2026
Operating Leases, 2027
Finance Lease, 2027
Operating Leases, 2028
Thereafter
Thereafter
Operating Leases, Total minimum lease payments
Finance Leases, Total minimum lease payments
Operating Leases, Less: amount of lease payments representing interest
Finance Lease, Less: amount of lease payments representing interest
Operating Leases, Present value of future minimum lease payments
Finance Lease, Present value of future minimum lease payments
Operating Leases, Less: Current leases obligations
Finance Lease, Less: Current leases obligations
Operating Leases, Long-term leases obligations
Finance Lease, Long-term leases obligations
LeasesTable [Table]
Leasing contracts period
CommitmentsAndContingenciesDisclosureTable [Table]
Collaboration And License Agreements Axis [Axis]
Royalty of net sales percentage
Sublicensing fees percentage
Annual license fee
Commitment, shares of common stock
Commitment, shares of common stock of Israeli subsidiary
Grants receivable, noncurrent
Recognized grant income
Royalty of net sales of other product percentage
Payment of fee upon the achievement of each regulatory milestone
Future milestone payments
Royalty expense
Invested amount for development
Revenue share percentage
Cost of services, other research and development expenses
Royalty of net sales
Royalty percentage on service revenue
Royalty percentage on sublease revenue
Grants receivable
Working capital
Restricted cash
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Payments for termination of joint venture
Equity interest valuation
Sub-license fee
Loan repayable term
Joint venture transferred amount
Aggregate purchase price
Warrants expire year
Net loss attributable to Orgenesis Inc
Weighted average number of common shares outstanding - basic
Weighted average number of common shares outstanding - diluted
Net loss per share - basic
Net loss per share - diluted
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount
No. of options granted
Exercise price
Stock options vesting period description
Fair value at grant
Expiration period
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Value of one common share
Dividend yield
Expected stock price volatility
Risk free interest rate
Expected term (years)
Number of Options - Options outstanding at the beginning of the year
Weighted Average Exercise Price - Options outstanding at the beginning of the year
Number of Options - Granted
Weighted Average Exercise Price - Granted
Number of Options - Exercised
Weighted Average Exercise Price - Exercised
Number of Options - Expired
Weighted Average Exercise Price - Expired
Number of Options - Forfeited
Weighted Average Exercise Price - Forfeited
Number of Options - Options outstanding at the end of the year
Weighted Average Exercise Price - Options outstanding at the end of the yea
Number of Options - Options exercisable at end of the year
Weighted Average Exercise Price - Options exercisable at end of the year
Number of Options - Forfeited
Number of Options - Cancelled
Weighted Average Exercise Price - Cancelled
Share-based payment arrangement, after forfeiture
Grants in period
Weighted average exercise price
Exercise Price
Number of Outstanding Options
Weighted Average Remaining Contractual Life
Aggregate Intrinsic Value
Number of Exercisable Options
Aggregate Exercisable Options Value
Number of options granted
Vesting peirod description
Vesting period description
Number of RSUs - Options outstanding at the beginning of the year
Number of RSUs - Granted
Number of RSUs - Expired
Number of RSUs - Forfeited
Number of RSUs - Options outstanding at the end of the year
CompensationRelatedCostsSharebasedPaymentsTable [Table]
Reason for issue of share or warrant
Number of shares issued
Warrants to purchase common stock
Warrant vesting
Warrant expiry date
Number of options granted
Restricted stock unit vesting period description
Number of shares granted
Number of reserved shares for common stock
Contractual life term
Stock options available for grants
Unrecognized compensation costs
Expiration period
Restricted Stock expense
RSUs unrecognized compensation costs
RSUs, to be recorded term
IncomeTaxDisclosureTable [Table]
Effective income tax rate reconciliation, at income tax rate
Operating loss carryforwards
Net operating loss carry forwards
Research and development expenses
Equity compensation
Employee benefits
Property, plants and equipment
Leases asset
Lease liability
Partnership Investment
Intangible assets
Bad debt allowance
Other
Deferred tax assets gross
Valuation allowance
Net deferred tax liabilities
Balance at the beginning of year
Deconsolidation of Octomera
Change during the year
Balance at end of year
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Line Items]
Total
Customer D (United States)
Balance as of beginning of period
Deconsolidation of Octomera
Additions
Collections
Allowances for credit losses
Exchange rate differences
Balance as of end of period
Balance as of beginning of period
Reconsolidation (deconsolidation) of Octomera
Deconsolidation of OBI
Additions
Realizations
Balance as of end of period
ResearchAndDevelopmentTable [Table]
Salaries and related expenses
Stock-based compensation
Subcontracting, professional and consulting services
Lab expenses
Depreciation expenses
Other research and development expenses
Less – grant
Total
ResearchDevelopmentTable [Table]
Intangiable asset purchase price valued by third party
Intangiable asset purchase price valued by third party
Common stock issue price
Description of ownership percentage
Intangible asset purchase price valued by third party
Payment as per agreement description
Interest expense on convertible loans
Foreign exchange loss, net
Other expense
Total
Total liabilities assumed:
Loss from deconsolidation of OBI
Total net liabilities deconsolidated
Total Accumulated Other Comprehensive loss deconsolidated
Profit from deconsolidation of Orgenesis Services SRL
Accounts payable related parties
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Stock Based Compensation
Compensation
Management and consulting fees
Related parties payables
Related parties payables
CommitmentsAndContingenciesTable [Table]
Prceedings actions taken by plaintiff description
Loss contingency, damages paid, value
Royalty guarantee commitments amount
Plaintiffs request damages amount
Litigation settlement interest percentage
Unsecured convertible debt
Monthly interest rate
Maturity date
Warrants awarded
Warrants exercise price
Principal amount of the loan and accrued interest
Issuance of shares
Litigation settlement, amount awarded from other party
Gain loss related to litigation settlement
Additional amount to be paid for failure litigation settlement amount awarded from other party
Subsequent Event [Table]
Subsequent Event [Line Items]
Investments
Ordinary shares
Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage
Warrants purchase percentage
Warrants exercise price
Additional warrants
Credit facility description
Warrant issued
Common stock, par value
Change in Contingent consideration.
Credit loss on convertible loan receivable.
Inducement expense on conversion of convertible loans.
Release of translation adjustment due to deconsolidation of octomera.
No Insider Trading Flag.
Noncontrolling interest adjustments to additional paid in capital.
Stock issued during period value warrants exercised.
Advance payments on account of grant.
Stock issued during period shares warrants exercised.
Contingent consideration non-current.
Adjustments to additional paid in capital redemption value of redeemable non controlling interest.
Adjustments to additional paid in capital deconsolidation.
Convertible loan induced conversion expenses.
Capital loss, net.
Credit loss related to obi.
Impairment of investment.
Increase decrease in effect of exchange differences on intercompany balances.
Net changes in operating leases.
Interest expense accrued on loans and convertible loans.
Increase decrease in related parties net.
Decrease in loan to associate entities.
Impact to cash resulting from deconsolidation
Impact to cash resulting from another deconsolidation.
Repayment of investment in longterm deposits.
Proceeds from transaction with redeemable non controlling interest that do not acquire control of subsidiary.
Receipt from purchaser.
Increase decrease in accounts payable related to purchase of property plant and equipment.
Extinguishment in connection with convertible loan restructuring.
Octomera LLC [Member]
ORGS [Member]
Schedule of annual depreciation rates property and equipment [Table text block].
Production Facility [Member]
Schedule of intangible assets useful lives [Table text block].
Technology [Member]
Know How [Member]
Impairment charges of other investment.
Treasury shares [Policy Text Block].
Reconsolidation Disclosure [Text Block]
Royalty percentage to be received on generate net revenues.
Metalmark [Member]
Unit Purchase Agreement [Member]
Milestone payments.
Maximum amount of sales milestone payments if total sales achieve specific levels.
10 Secured Promissory Notes [Member]
Octomera [Member]
Business combination recognized identifiable assets acquired and liabilities assumed liabilities net.
Know How Technology [Member]
Business acquisition cost of acquired entity transaction cost.
Revaluation expense.
Summary Of Key Valuation Input Table [Text Block]
Measurement Input Standard Deviation [Member]
Possible Trigger Event Examination.
Measurement Input Trigger Event [Member]
Measurement Input Trigger Events [Member]
Butterfly Biosciences Sarl [Member]
Revacel Srl [Member]
Revatis [Member]
Equity method investments and loans to associates.
Equity method investment exchange rate difference.
Therapies [Member]
Eliminations [Member]
Cost of revenue excluding depreciation and amortization expenses.
Gross profit excluding depreciation and amortization expenses.
Research and development expense excluding depreciation and amortization expenses.
Operating expense excluding depreciation and amortization expenses.
Finance fees related to convertible loans to equity.
2017 Equity Incentive Plan [Member]
Global Share Incentive Plan 2012 [Member]
Options Granted To Employees [Member]
Employees [Member]
Vesting period.
Fair value at grant
Expiration period
Securities Purchase Agreement [Member]
Warrant alternated cashless exercise, description.
Transaction fees.
Warrant One [Member]
Exercise Price One [Member]
Exercise Price Two [Member]
Exercise Price Three [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
Exercise Price Six [Member]
Exercise Price Seven [Member]
Exercise Price Eight [Member]
Exercise Price Nine [Member]
Exercise Price Ten [Member]
Exercise Price Eleven [Member]
Exercise Price Twelve [Member]
Exercise Price Thirteen [Member]
Exercise Price Fourteen [Member]
Exercise Price Fifteen [Member]
Exercise Price Sixteen [Member]
Exercise Price Seventeen [Member]
Exercise Price Eighteen [Member]
Exercise Price Nineteen [Member]
Exercise Price Twenty [Member]
Exercise Price Twenty One [Member]
Exercise Price Twenty Two [Member]
Exercise Price Twenty Three [Member]
Exercise Price Twenty Four [Member]
Exercise Price Twenty Five [Member]
Exercise Price Twenty Six [Member]
Exercise Price Twenty Seven [Member]
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments granted weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments exercised weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments expirations weighted average exercise price.
Schedule of property plant and equipment by geographical location [Table text block].
Goodwill deconsolidation.
Exercise Price Twenty Eight [Member]
Loans Disclosure [Text Block]
Debt instrument maturity year.
Short Term Debt One [Member]
Short Term Debt Two [Member]
Short Term Debt Three [Member]
Debt Exchange Agreements [Member]
Schedule Of Warrants Granted [Table Text Block]
April 07, 2024 [Member]
April 05 2024 [Member]
August 21 2024 [Member]
August 21 2024 One [Member]
September 06 2024 [Member]
September 10 2024 [Member]
September 09 2024 [Member]
September 17 2024 [Member]
September 30 2024 [Member]
October 03 2024 [Member]
October 22 2024 [Member]
Options Granted to Employees and Directors [Member]
Masthercell Global [Member]
Options Granted To Non Employees [Member]
Share based compensation arrangement by share based payment award options grants in period vesting period description.
October 30 2024 [Member]
November 04 2024 [Member]
November 14 2024 [Member]
November 15 2024 [Member]
November 29 2024 [Member]
December 13 2024 [Member]
December 19 2024 [Member]
Share based compensation arrangement by share based payment award options cancelled in period.
Share based compensation arrangements by share based payment award options cancelled in period weighted average exercise price.
November 30 2024 [Member]
December 31 2024 [Member]
December 31 2024 One [Member]
December 31 2024 Two [Member]
December 31 2024 Three [Member]
December 31 2024 Four [Member]
December 31 2024 Five [Member]
December 31 2024 Six [Member]
December 31 2024 Seven [Member]
December 31 2024 Eight [Member]
Loan Agreement [Member]
Convertible Loans One [Member]
Convertible Loans Two [Member]
Convertible Loans Three [Member]
Convertible Loans Four [Member]
Convertible Loans [Member]
Convertible Loans Five [Member]
Convertible Loans Six [Member]
Convertible Loans Seven [Member]
Convertible Loans Eight [Member]
Convertible Loans Nine [Member]
Employee service sharebased compensation nonvested total compensation cost not yet recognized and period for recognition in years.
Convertible Loans Repaid One [Member]
Three Convertible Debt Holders [Member]
Description of warrant vesting.
Koligo Therapeutics Inc [Member]
Lender [Member]
Borrower [Member]
Convertible Loan Agreements [Member]
Offshore Investor [Member]
Leases Disclosure [Text Block]
Schedule of Warrants Grants [Table Text Block]
Offices [Member]
Leases of lessee balance sheet disclosures [Table text block].
Finance lease cost.
Leases asset.
Deferred tax liabilities lease liability.
Deferred tax liabilities goodwill and intangible assets intangible assets bad debt allowance.
Lessee lease liability maturity [Table text block].
Deferred tax assets valuation allowance deconsolidation.
Schedule Of Breakdown Of Revenues Per Customer [Table Text Block]
Customer D [Member]
Schedule of right of use assets by geographical location.
Accounts receivable deconsolidation.
Accounts receivable additions.
Accounts receivable collections.
Accounts receivable allowances for doubtful accounts.
Exchange rate differences of accounts receivable.
Royalty of net sales percentage.
Collaboration And License Agreements Axis
TelHashomer Medical Research Infrastructure and Services Ltd Thm [Member]
Sublicensing fees percentage.
Annual license fee.
Contract with customer liability deconsolidation.
Contract with customer liability realizations.
PhaseI Clinical Trials [Member]
Lab expenses.
PhaseII Clinical Trials [Member]
Grant.
Phase III Clinical Trials [Member]
First Product By The FDA [Member]
Worldwide Net Sales Of Products [Member]
Sales Milestone [Member]
Commitment shares of common stock.
Commitment shares of common stock of subsidiary.
Israelus Binational Industrial Research And Development Foundation [Member]
Columbia License Agreement [Member]
Royalty of net sales of other products percentage.
Payment of fee upon achievement of each regulatory milestone.
California University Joint Research Agreement [Member]
Intangiable asset purchase price valued by third party.
Broaden [Member]
Caerus Therapeutics Inc [Member]
Shares issued percentage above market price.
Theracell [Member]
Payment description as per agreement.
Future milestone payments.
Tissue Genesis, LLC [Member]
Interest expense on convertible loans.
Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.
Total financial expenses.
Savicell Agreement [Member]
Invested amount for development plan.
Stromatis Agreement [Member]
Revenue share percentage.
Cost of services other research and development expenses.
HMGU [Member]
Royalty of service revenue.
Annual royalty.
Deconsolidation Of Subsidiaries [Text Block]
Royalty of sub-lease revenue.
European Innovation Council And SMEs Executive Agency [Member]
Grant Funding Agreement [Member]
Working capital.
Grants From Other [Member]
Payments for termination of joint venture.
Mircod LLC [Member]
SubLicense Agreements [Member]
Share based compensation arrangement by share based payment award options grant in period gross.
Orgenesis Biotech Israel Limited [Member]
Deconsolidation Loss Amount.
Loan repayable term.
Deep Med IO Ltd [Member]
Joint Venture Agreement [Member]
Joint venture transferred amount.
Asset Purchase Agreement [Member]
Orgenesis Korea [Member]
Deconsolidation profit amount.
Accumulated other comprehensive income deconsolidated.
Orgenesis Belgium SRL And Orgenesis SRL [Member]
Orgenesis Belgium SRL [Member]
Orgenesis Services SRL [Member]
Board Members [Member]
Schedule Of Related Parties Presented In Consolidated Balance Sheets [Table Text Block]
Nonexecutive Directors [Member]
Options and Warrants [Member]
Southern Israel Bridging Fund Two LP [Member]
Mr Amir Hasidim [Member]
Litigation settlement interest percentage.
Shares upon Conversion of Convertible Loans [Member]
Unsecured Convertible Note Agreements [Member]
Consultation Agreement [Member]
Additional amount to be paid for failure litigation settlement amount awarded from other party.
Unsecured Convertible Note Two Agreements [Member]
Equity Purchase Agreement [Member]
Registration Rights Agreement [Member]
Convertible Loan Agreement [Member]
Warrants to purchase percentage.
Additional warrants.
Statement Of Income Location Balance [Axis]
Research And Development Expenses [Member]
Williamsburg Venture Holdings LLC [Member]
Schedule Of Stockholders Equity Note Warrant Or Rights [Text Block]
Goodwill impairment.
Repayment of loan.
Options, RSUs and Warrants [Member]
Contract with customer liability reconsolidation (deconsolidation).
Grant amount.
Financial expenses.
Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Customer A [Member]
Customer B [Member]
Customer C [Member]
Office Furniture and Computers [Member]
Lab Equipment [Member]
Advance Payment [Member]
Assets, Current
Assets, Noncurrent
Assets [Default Label]
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Treasury Stock, Value
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Income (Loss)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
CapitalLossNet
NetChangesInOperatingLeases
InterestExpenseAccruedOnLoansAndConvertibleLoans
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Inventories
Increase (Decrease) in Other Operating Assets
IncreaseDecreaseInRelatedPartiesNet
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Deferred Income Taxes
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Interest in Subsidiaries and Affiliates
ImpactToCashResultingFromDeconsolidation
ImpactToCashResultingFromAnotherDeconsolidation
Payments for (Proceeds from) Long-Term Investments
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Repayments of Debt
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
ExtinguishmentInConnectionWithConvertibleLoanRestructuring
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Research, Development, and Computer Software, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Goodwill and Intangible Assets, Policy [Policy Text Block]
Lessee, Leases [Policy Text Block]
Intangible Assets, Current
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNet
Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment
Business Combination, Recognized Asset Acquired, Asset
Business Combination, Recognized Liability Assumed, Liability, Current
Business Combination, Recognized Liability Assumed, Liability, Noncurrent
Business Combination, Recognized Liability Assumed, Liability
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value
Debt Instrument, Measurement Input
EquityMethodInvestmentsAndLoansToAssociates
CostOfRevenueExcludingDepreciationAndAmortizationExpenses
ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses
ImpairmentOfInvestment
Depreciation, Depletion and Amortization
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Gross
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization
FinanceLeaseCost
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, Undiscounted Excess Amount
Restricted Cash
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Deferred Tax Liabilities, Property, Plant and Equipment
DeferredTaxLiabilitiesLeaseLiability
Deferred Tax Liabilities, Intangible Assets
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Liabilities, Net
DeferredTaxAssetsValuationAllowanceDeconsolidation
AccountsReceivableDeconsolidation
ExchangeRateDifferencesOfAccountsReceivable
Contract with Customer, Liability, Current
ContractWithCustomerLiabilityDeconsolidation
Increase (Decrease) in Contract with Customer, Liability
ContractWithCustomerLiabilityRealizations
Share-Based Payment Arrangement, Expense
GrantAmount
Other Income
FinancialExpenses
DeconsolidationLossAmount
DeconsolidationProfitAmount
Recognized loss from deconsolidation